A new era of immune therapy in multiple myeloma

Blood

Volumn 128, Issue 3, 2016, Pages 318-319

  Tai, Yu Tzu ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DARATUMUMAB; FC RECEPTOR; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOTOXIN; ISATUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT PHAGOCYTOSIS; APOPTOSIS; B LYMPHOCYTE; BONE MARROW DERIVED MONONUCLEAR CELL; BURST FORMING UNIT E; CANCER IMMUNOTHERAPY; COCULTURE; COLONY FORMING UNIT GM; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYSOSOME; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; IMMUNOLOGY;

HUMANS; MULTIPLE MYELOMA;

EID: 84979086818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-719856     Document Type: Note

References (8)

1. + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
2. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424-1433.
3. Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991;77(5):1071-1079.
4. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. 1994;84(9):3017-3025.
5. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
6. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
7. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
8. Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399-408.